Dutch multinational technology company Royal Philips has received CE mark approval for its Philips V60 Plus Ventilator.
This solution builds on its noninvasive ventilation (NIV) gold standard platform, integrating NIV and high flow therapy (HFT) in a single device.
The device helps clinicians to quickly adjust therapies according to the condition of patients without switching devices.
V60 Plus is designed for early intervention in respiratory failure and enables clinicians to improve patient outcomes with less invasive respiratory care therapies.
Although early implementation with NIV is associated with less endotracheal intubation, sometimes clinicians face challenges when taking patients off this therapy.
Philips Hospital Respiratory Care business leader Jim Alwan said: “When treating respiratory patients in Intensive and Emergency Care settings, it’s critical for clinicians to be able to wean efficiently or to quickly escalate care depending on their patient’s condition and specific needs.
“This often means complex workflows and alternating devices in time-sensitive situations. We are excited to offer a comprehensive noninvasive solution that enables quick therapy and interface transitions, so clinicians can focus on providing for their patients while spending less time setting up equipment.”
Stockholm-based St. Goran Hospital NIV programme leader Peter Lindberg said: “We are delighted with the high flow function of the V60 Plus. It saves us a lot of time and space as we can use the same equipment for both NIV and high flow.
“When you need to wean patients from NIV to HFT, it is very simple with the one device. Additionally, the cannula is high quality, easy to adjust, soft against the patient’s skin and V60 flow is much quieter than our standalone high flow system.”
Following the CE mark approval, V60 Plus is available for sale in Europe. The firm has submitted a 510k application to the US Food and Drug Administration (FDA) for the device.